RxSight, Inc. Stock News

RxSight (NASDAQ:RXST) and National Vision (NASDAQ:EYE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations. Valuation & Earnings This table compares RxSight and National Visions gross revenue, earnings per share (EPS) and []

RxSight (NASDAQ:RXST) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends. Earnings & Valuation This table compares RxSight and National Visions revenue, earnings per share and valuation. Gross []

Shares of RxSight Inc (NASDAQ:RXST) have received an average rating of Buy from the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that []

Shares of RxSight Inc (NASDAQ:RXST) have been assigned an average recommendation of Buy from the six brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have []

RxSight (NASDAQ:RXST) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report issued on Friday, Zacks.com reports. According to Zacks, RxSight Inc. is a commercial-stage medical technology company focuses on patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens(R), RxSight []

RxSight (NASDAQ:RXST) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Institutional & Insider Ownership 20.4% of RxSight shares are owned by institutional investors. 2.3% of National Vision []

SVB Leerink reiterated their buy rating on shares of RxSight (NASDAQ:RXST) in a research report sent to investors on Sunday morning, AnalystRatings.com reports. SVB Leerink currently has a $20.00 target price on the stock. RXST has been the subject of a number of other research reports. JPMorgan Chase & Co. assumed coverage on shares of []

RxSight, Inc. (RXST) CEO Ron Kurtz On Q3 2021 Results - Earnings Call Transcript

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after th

ALISO VIEJO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported fin

ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Heal

RxSight has commercialized the first and only FDA approved customizable intraocular lens.

ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after t

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTec

ALISO VIEJO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company, today announced that Steve Everly has joined the company as its Vice Pres